AYTU – Aytu Bioscience News

AYTU - Aytu Bioscience News

Latest news headlines for Aytu Bioscience Inc with market analysis and analyst commentary. Samsung Foundry’s upcoming chip manufacturing plant in Austin, Texas will require an investment of $17 billion, according to the latest documents. – SamMobile Companies

Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021 ACCESSWIRE – Wed Feb 10, 7:00AM CST

CMTX – Wed Feb 10, 7:00AM CST

– Record date for each Special Meeting of Stockholders is February 5, 2021 –

AYTU : 8.74 (-3.43%)

NEOS : 1.1800 (-6.35%)

Play Stocks With Rising P/E to Realize Solid Gains Zacks – Mon Feb 8, 5:57AM CST

Sanghamitra Saha – ZACKS – Mon Feb 8, 5:57AM CST

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

CEO : 112.78 (-0.54%)

GFI : 9.39 (-3.20%)

LEN : 94.56 (+0.95%)

QTS : 63.97 (-2.43%)

GTY : 28.68 (-0.45%)

AYTU : 8.74 (-3.43%)

Aytu BioScience to Report Second Fiscal 2021 Results and Provide Business Update on Thursday, February 11, 2021 ACCESSWIRE – Thu Feb 4, 7:00AM CST

CMTX – Thu Feb 4, 7:00AM CST

Live Conference Call and Webcast at 4:30 PM ET

AYTU : 8.74 (-3.43%)

Aytu BioScience Announces Completion of Healight(TM) Safety Study in Critically Ill COVID-19 Patients ACCESSWIRE – Mon Dec 28, 7:05AM CST

CMTX – Mon Dec 28, 7:05AM CST

First Safety Study Utilizing Ultraviolet A Light Catheter as a Prospective Anti-Infective in Critically Ill, Intubated SARS-Cov-2 Patients

AYTU : 8.74 (-3.43%)

Lifshitz Law Firm, P.C. Announces Investigation of AJRD, CATM, EXPC, GNBF, LNKB, NEOS, AYTU, QEP, FANG, RP, RNET, and VSAT PR Newswire – PRF – Thu Dec 24, 9:49PM CST

CMTX – Thu Dec 24, 9:49PM CST

, /PRNewswire/ —

AJRD : 52.25 (-0.31%)

CATM : 38.82 (+0.08%)

EXPC : 17.41 (+3.38%)

GNBF : 83.9000 (-0.12%)

LNKB : 11.9500 (+2.58%)

NEOS : 1.1800 (-6.35%)

AYTU : 8.74 (-3.43%)

QEP : 3.39 (-1.17%)

FANG : 67.77 (-1.61%)

RP : 86.99 (+0.16%)

RNET : 10.89 (-0.55%)

VSAT : 60.06 (-0.43%)

Aytu BioScience Announces Closing of $28.75 Million Bought Deal Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares ACCESSWIRE – Tue Dec 15, 11:00AM CST

CMTX – Tue Dec 15, 11:00AM CST

ENGLEWOOD, CO / ACCESSWIRE / December 15, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), (“Aytu” or “the Company”), a specialty pharmaceutical company focused on commercializing novel products that address…

AYTU : 8.74 (-3.43%)

Aytu BioScience to Present at the LD Micro Virtual Investor Conference on Tuesday, December 15 at 2:20pm ET ACCESSWIRE – Mon Dec 14, 7:01AM CST

CMTX – Mon Dec 14, 7:01AM CST

ENGLEWOOD, CO / ACCESSWIRE / December 14, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the “Company”), a specialty pharmaceutical company focused on commercializing novel products that address significant…

AYTU : 8.74 (-3.43%)

NEOS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of NEOS and Encourages Investors to Contact the Firm GlobeNewswire – Fri Dec 11, 10:41AM CST

CMTX – Fri Dec 11, 10:41AM CST

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Neos Therapeutics, Inc. (NASDAQ: NEOS) breached their fiduciary…

NEOS : 1.1800 (-6.35%)

AYTU : 8.74 (-3.43%)

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Neos Therapeutics, Inc. Merger GlobeNewswire – Fri Dec 11, 9:38AM CST

CMTX – Fri Dec 11, 9:38AM CST

Rigrodsky & Long, P.A. announces that it is investigating Neos Therapeutics, Inc. (“Neos”) (NASDAQ GS: NEOS) regarding possible breaches of fiduciary duties and other violations of law related to Neos’…

NEOS : 1.1800 (-6.35%)

AYTU : 8.74 (-3.43%)

Aytu BioScience Increases Previously Announced Bought Deal Offering to $25.0 Million ACCESSWIRE – Thu Dec 10, 10:10PM CST

CMTX – Thu Dec 10, 10:10PM CST

ENGLEWOOD, CO / ACCESSWIRE / December 10, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs,…

AYTU : 8.74 (-3.43%)

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Neos Therapeutics, Inc. PR Newswire – PRF – Thu Dec 10, 6:35PM CST

CMTX – Thu Dec 10, 6:35PM CST

, /PRNewswire/ — Rowley Law PLLC is investigating potential securities law violations by Neos Therapeutics, Inc. (NASDAQ: NEOS) and its board of directors concerning the proposed acquisition of the company…

NEOS : 1.1800 (-6.35%)

AYTU : 8.74 (-3.43%)

Aytu BioScience Announces $10.0 Million Bought Deal Offering ACCESSWIRE – Thu Dec 10, 4:38PM CST

CMTX – Thu Dec 10, 4:38PM CST

ENGLEWOOD, CO / ACCESSWIRE / December 10, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs,…

AYTU : 8.74 (-3.43%)

SHAREHOLDER ALERT: WeissLaw LLP Investigates Neos Therapeutics, Inc. PR Newswire – PRF – Thu Dec 10, 3:52PM CST

CMTX – Thu Dec 10, 3:52PM CST

, /PRNewswire/ —  is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neos Therapeutics, Inc. (“NEOS” or the “Company”) (NASDAQ: NEOS) in connection…

NEOS : 1.1800 (-6.35%)

AYTU : 8.74 (-3.43%)

Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company GlobeNewswire – Thu Dec 10, 7:00AM CST

CMTX – Thu Dec 10, 7:00AM CST

— Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022

AYTU : 8.74 (-3.43%)

NEOS : 1.1800 (-6.35%)

Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company ACCESSWIRE – Thu Dec 10, 5:01AM CST

CMTX – Thu Dec 10, 5:01AM CST

Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022Aytu adds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s footprint…

AYTU : 8.74 (-3.43%)

NEOS : 1.1800 (-6.35%)

Diagnostic Capabilities Remain of Utmost Importance as Cases Surge Worldwide PR Newswire – PRF – Wed Nov 25, 8:00AM CST

CMTX – Wed Nov 25, 8:00AM CST

, /PRNewswire/ — As of earlier this week, the U.S. has reported more than 12.4 million cases and over 257,600 deaths, . Dr. , the National Institute of Allergy and Infectious Diseases, has also…

CYDY : 6.1800 (+11.55%)

AYTU : 8.74 (-3.43%)

NVAX : 298.26 (-0.03%)

IBIO : 2.34 (-10.00%)

Innovative Software Solutions Arise for a Returning Workforce PR Newswire – PRF – Wed Nov 18, 8:02AM CST

CMTX – Wed Nov 18, 8:02AM CST

, /PRNewswire/ — According to recent reports, cases are once again surging across with at least 37 states seeing a rise in hospitalizations. More than 11.4 million Americans have now been infected…

EPAZ : 0.0620 (+45.88%)

ONTX : 1.1600 (unch)

TPTW : 0.0790 (-7.06%)

TNXP : 2.00 (+22.70%)

AYTU : 8.74 (-3.43%)

Male Infertility Market – Growth, Trends, and Forecasts (2020 – 2025) PR Newswire – PRF – Tue Nov 17, 9:20AM CST

CMTX – Tue Nov 17, 9:20AM CST

, /PRNewswire/ — The Male Infertility Market is expected to register a CAGR of 7.5% during the forecast period. This is attributing to the increasing incidence of infertility, high adoption of assisted…

AYTU : 8.74 (-3.43%)

Source: www.barchart.com


Samsung to build a $17 billion chip manufacturing plant in Texas

Samsung to build a $17 billion chip manufacturing plant in Texas

It was reported last month that Samsung is looking to set up a $10 billion chip manufacturing facility in Austin, Texas, in the US. It is now being reported that the company might invest a lot more than it was initially reported. According to the documents filed by Samsung Foundry in Arizona, New York, and Texas, the upcoming chip plant is expected to cost over $17 billion.

Samsung’s potential chip manufacturing facility in Austin, Texas, will reportedly create around 1,800 jobs. If everything goes according to the plant, the upcoming chip facility will go online in the fourth quarter of 2023. While the company hasn’t revealed which fabrication process the new plant would be designed for, it is possible that the company could make 3nm (MBCFET) chips there.

The company only makes chips based on leading processes such as 7nm and 5nm in South Korea. Its existing S2 line in Texas makes 14nm and 11nm chips, which are not modern. However, Samsung Foundry has enough customers in the US, including IBM, Nvidia, Qualcomm, and Tesla, which means it could set up a dedicated fab in the country for those clients. As most consumer electronics products and automobiles are becoming smarter, the demand for advanced logic chips has spiked over the past few years.

Samsung’s current plan that was submitted to the government of Texas includes a 7 million square feet chip plant on the company’s 640-acre site. The new fabrication facility will be adjacent to Samsung’s existing S2 plant, which means the company has no plans to upgrade the S2 plant to more recent processes in the near future. In comparison, TSMC’s upcoming plant in Arizona will be relatively smaller.

The company expects the new chip plant to have an economic output of around $8.64 billion and salaries of around $7.32 billion to permanent employees during the first 20 years of its operation. According to Reuters, Samsung Foundry is seeking a combined tax subsidy of $805.5 million over the next 20 years from the city of Austin and Travis County.

Source: www.sammobile.com

Author: SamMobile


Is First American Financial Corporation (FAF) a Keeper?

Is First American Financial Corporation (FAF) a Keeper?

First American Financial Corporation (NYSE:FAF) went up by 4.16% from its latest closing price compared to the recent 1-year high of $66.78. The company’s stock price has collected 5.46% of gains in the last five trading sessions. Press Release reported 17 hours ago that First American Financial Reports Results for the Fourth Quarter and Full Year of 2020

First American Financial Corporation (NYSE:FAF) scored a price-to-earnings ratio above its average ratio, recording 10.19 x from its present earnings ratio. Plus, the 36-month beta value for FAF is at 1.16. Opinions of the stock are interesting as 4 analysts out of 6 who provided ratings for First American Financial Corporation declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”

Sponsored

The average price from analysts is $65.80, which is $6.64 above the current price. FAF currently public float of 108.26M and currently shorts hold a 1.34% ratio of that float. Today, the average trading volume of FAF was 673.85K shares.

FAF stocks went up by 5.46% for the week, with a monthly jump of 6.08% and a quarterly performance of 19.10%, while its annual performance rate touched -7.76%. The volatility ratio for the week stands at 2.52% while the volatility levels for the past 30 days are set at 2.48% for First American Financial Corporation. The simple moving average for the period of the last 20 days is 6.14% for FAF stocks with a simple moving average of 13.05% for the last 200 days.

Many brokerage firms have already submitted their reports for FAF stocks, with Stephens repeating the rating for FAF by listing it as a “Equal-Weight.” The predicted price for FAF in the upcoming period, according to Stephens is $48 based on the research report published on April 20th of the previous year 2020.

Keefe Bruyette, on the other hand, stated in their research note that they expect to see FAF reach a price target of $57. The rating they have provided for FAF stocks is “Outperform” according to the report published on April 08th, 2020.

Compass Point gave a rating of “Buy” to FAF, setting the target price at $74 in the report published on March 05th of the previous year.

After a stumble in the market that brought FAF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.81% of loss for the given period.

Volatility was left at 2.48%, however, over the last 30 days, the volatility rate increased by 2.52%, as shares surge +5.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.83% upper at present.

During the last 5 trading sessions, FAF rose by +5.46%, which changed the moving average for the period of 200-days by +21.00% in comparison to the 20-day moving average, which settled at $54.38. In addition, First American Financial Corporation saw 11.49% in overturn over a single year, with a tendency to cut further gains.

Reports are indicating that there were more than several insider trading activities at FAF starting from OMAN MARK C, who purchase 4,000 shares at the price of $47.78 back on Oct 23. After this action, OMAN MARK C now owns 38,092 shares of First American Financial Corporation, valued at $191,125 using the latest closing price.

DEGIORGIO KENNETH D, the Executive Vice President of First American Financial Corporation, sale 30,000 shares at $65.90 during a trade that took place back on Mar 06, which means that DEGIORGIO KENNETH D is holding 372,863 shares at $1,977,000 based on the most recent closing price.

Current profitability levels for the company are sitting at:

  • +15.32 for the present operating margin
  • The net margin for First American Financial Corporation stands at +11.41. The total capital return value is set at 17.40, while invested capital returns managed to touch 13.28. Equity return is now at value 14.20, with 5.30 for asset returns.

    Based on First American Financial Corporation (FAF), the company’s capital structure generated 45.56 points at debt to equity in total, while total debt to capital is 31.30. Total debt to assets is 17.48, with long-term debt to equity ratio resting at 43.57. Finally, the long-term debt to capital ratio is 29.93.

    When we switch over and look at the enterprise to sales, we see a ratio of 1.39, with the company’s debt to enterprise value settled at 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.31.

    Source: newsheater.com

    Author: By Denise Gardner


    AYTU - Aytu Bioscience News

    Leave a Comment